Skip to main content
padlock icon - secure page this page is secure

Efficacy and Safety of Rizatriptan Versus Standard Care During Long-term Treatment for Migraine

Buy Article:

$52.00 + tax (Refund Policy)

Rizatriptan is a novel, selective 5-HT1B/1D receptor agonist with a rapid onset of action after oral dosing for the acute treatment of migraine. We conducted a long-term (up to 1 year), multicenter, randomized study in 1831 patients treating more than 46 000 attacks to compare the efficacy and tolerability of rizatriptan 5 mg and 10 mg to standard care medications routinely used for the acute treatment of migraine attacks. Both doses of rizatriptan were highly effective, without evidence of tachyphylaxis. Rizatriptan 10 mg was consistently superior (P<0.05), both to the 5-mg dose and to standard care, in providing relief in 90% of attacks, with 50% pain-free by 2 hours after dosing. The most common dose-related adverse events were nausea, somnolence, and asthenia/fatigue. Based on this large, multicenter, long-term trial, rizatriptan is an important new oral agent for the acute treatment of migraine.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: 5-HT1D receptor agonist; MK-462; migraine; rizatriptan

Document Type: Research Article

Affiliations: 1: From Merck Research Laboratories, West Point, Penn (Drs. Block and Reines, Mr. Polis, and Ms. Smith) and the 2: San Francisco (Calif) Headache Clinic (Dr. Goldstein).

Publication date: November 1, 1998

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more